Applications of Droplet Digital PCR in Assessing AAV-based Gene Therapy Performance

Peter Clarner

Scientist I, Gene Therapy Accelerator Unit (GTxAU) ‑ Biogen

Pete joined Biogen in 2012, and for 7 years he was a member of the Bioassay and Gene Therapy group within the Analytical Development department (PO&T). There he supported the characterization and development of clinical stage protein biologic and AAV vector‑based gene therapy programs. He is now a Scientist in the Gene Therapy Accelerator Unit within the Biotherapeutics and Medicinal Sciences department (R&D). There he continues to focus on vector analytics for preclinical programs and platform initiative with expertise in in vitro method development.

Within the GTxAU he also supports portfolio, platform, and technology development. Over the past 5 years Pete has gained extensive experience with the ddPCR technology, developing and qualifying multiple methods on the platform. He is a recognized ddPCR expert at Biogen and SME for its applications, particularly in AAV vector characterization. Pete holds a Bachelor’s degree in Biology from Boston College and a Professional Master of Science degree in Biotechnology from Northeastern University.